EconBiz - Find Economic Literature
    • Logout
    • Change account settings
  • A-Z
  • Beta
  • About EconBiz
  • News
  • Thesaurus (STW)
  • Academic Skills
  • Help
  •  My account 
    • Logout
    • Change account settings
  • Login
EconBiz - Find Economic Literature
Publications Events
Search options
Advanced Search history
My EconBiz
Favorites Loans Reservations Fines
    You are here:
  • Home
  • Search: subject:"Tobramycin"
Narrow search

Narrow search

Year of publication
Subject
All
Colistin 2 Tobramycin 2 Aminoglycosides 1 Amphotericin B 1 Antibacterials 1 Bacterial-infections 1 Beta-lactams 1 Cost analysis 1 Cystic-fibrosis 1 Inhalation 1 Liver transplant 1 Norfloxacin 1 Pharmacoeconomics 1 Postoperative infections 1 Pseudomonal-infections 1 Respiratory-tract-infections 1 Reviews-on-treatment 1
more ... less ...
Online availability
All
Undetermined 2
Type of publication
All
Article 2
Language
All
Undetermined 2
Author
All
Bottema, Jan T. 1 Goa, Karen L. 1 Klompmaker, Ids J. 1 Lamb, Harriet M. 1 Maring, John K. 1 Slooff, Maarten J.H. 1 Ten Vergert, Elisabeth M. 1 Zwaveling, Jan H. 1 van Enckevort, Petra J. 1
more ... less ...
Published in...
All
Disease Management and Health Outcomes 1 PharmacoEconomics 1
Source
All
RePEc 2
Showing 1 - 2 of 2
Cover Image
Cost Effectiveness of Selective Decontamination of the Digestive Tract in Liver Transplant Patients
van Enckevort, Petra J.; Zwaveling, Jan H.; Bottema, Jan T. - In: PharmacoEconomics 19 (2001) 5, pp. 523-530
Objective: To assess the cost effectiveness of selective decontamination of the digestive tract (SDD) in liver transplant patients. Design: Randomised, placebo-controlled, double-blind trial with an integrated economic evaluation. Setting: Two university hospitals in The Netherlands. Cost...
Persistent link: https://www.econbiz.de/10005590379
Saved in:
Cover Image
Management of Patients with Cystic Fibrosis: Defining the Role of Inhaled Tobramycin
Lamb, Harriet M.; Goa, Karen L. - In: Disease Management and Health Outcomes 6 (1999) 2, pp. 93-108
toxicity, is sometimes used in this patient group. Inhaled tobramycin, colistin (or colistimethate) and beta-lactam agents … be compared in clinical trials. Recently, tobramycin solution for inhalation (TOBI(R)) has been developed in an attempt …. aeruginosa infection, 3 courses of a 28-day on/28-day off regimen of inhaled tobramycin (TOBI(R)) significantly improved lung …
Persistent link: https://www.econbiz.de/10005404686
Saved in:
A service of the
zbw
  • Sitemap
  • Plain language
  • Accessibility
  • Contact us
  • Imprint
  • Privacy

Loading...